Get to know our clinical trials
Clinical trial of Epcoritamab in combination with R-CHOP compared to R-CHOP in subjects with newly diagnosed Diffuse Large B-Cell Lymphoma. Immunotherapy
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE THE EFFICACY AND SAFETY OF THE STUDY DRUG (EPCORITAMAB) WHEN ADMINISTERED IN COMBINATION WITH STANDARD TREATMENTS, NAMELY R-CHOP (RITUXIMAB, CYCLOPHOSPHAMIDE, OXORUBICIN, VINCRISTINE AND PREDNISONE) FOR NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).
Technical Summary
- PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPCORITAMAB IN COMBINATION WITH R-CHOP COMPARED TO R-CHOP IN SUBJECTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).
- Code EudraCT: 2021-000168-31
- Protocol number: M20-621
- Promoter: Abbvie Spain SLU
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.